Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.010x

Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-64.53 Million ≈ $-75.45 Million USD) by net assets (€6.39 Billion ≈ $7.47 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tianjin Zhong Xin Pharmaceutical Group C (2TZ) total market value for the company's overall valuation and market capitalisation.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited ranked by their cash flow conversion efficiency. Explore 2TZ cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
UEM Sunrise Bhd KLSE:5148	0.007x
Alpargatas S.A SA:ALPA3	0.040x
Beingmate Baby & Child Food Co Ltd SHE:002570	0.013x
Aeon Credit Service Bhd KLSE:5139	-0.076x
Qingmu Digital Technology Co.Ltd. SHE:301110	N/A
CoinShares PLC Ordinary Shares NASDAQ:CSHR	-0.001x
Sam Engineering Equipment KLSE:9822	-0.031x
MiMedx Group Inc NASDAQ:MDXG	0.123x

Annual Cash Flow Conversion Efficiency for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025. View today's stock price for Tianjin Zhong Xin Pharmaceutical Group C for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€7.10 Billion ≈ $8.30 Billion	€461.07 Million ≈ $539.03 Million	0.065x	-44.87%
2024-12-31	€7.85 Billion ≈ $9.18 Billion	€924.67 Million ≈ $1.08 Billion	0.118x	+13.69%
2023-12-31	€6.65 Billion ≈ $7.77 Billion	€688.49 Million ≈ $804.91 Million	0.104x	+0.23%
2022-12-31	€6.55 Billion ≈ $7.66 Billion	€677.25 Million ≈ $791.77 Million	0.103x	-21.01%
2021-12-31	€6.51 Billion ≈ $7.62 Billion	€852.40 Million ≈ $996.55 Million	0.131x	+15.96%
2020-12-31	€5.95 Billion ≈ $6.96 Billion	€671.42 Million ≈ $784.96 Million	0.113x	+25.79%
2019-12-31	€5.52 Billion ≈ $6.46 Billion	€495.49 Million ≈ $579.28 Million	0.090x	+29.50%
2018-12-31	€5.05 Billion ≈ $5.91 Billion	€350.14 Million ≈ $409.36 Million	0.069x	+8165.98%
2017-12-31	€4.63 Billion ≈ $5.41 Billion	€-3.97 Million ≈ $-4.64 Million	-0.001x	-100.88%
2016-12-31	€4.30 Billion ≈ $5.03 Billion	€417.77 Million ≈ $488.42 Million	0.097x	+10.55%
2015-12-31	€4.11 Billion ≈ $4.80 Billion	€360.58 Million ≈ $421.56 Million	0.088x	-9.77%
2014-12-31	€2.95 Billion ≈ $3.44 Billion	€286.85 Million ≈ $335.36 Million	0.097x	+17.45%
2013-12-31	€2.57 Billion ≈ $3.01 Billion	€213.44 Million ≈ $249.53 Million	0.083x	--

About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited

STU:2TZ Germany Drug Manufacturers - Specialty & Generic

Market Cap

$692.11 Million

€592.00 Million EUR

Market Cap Rank

#10718 Global

#1244 in Germany

Share Price

€2.96

Change (1 day)

+8.82%

52-Week Range

€2.11 - €3.15

All Time High

€3.15